BACKGROUND: To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS). METHODS:Five hundred and fifty-two Fijian infants were stratified by ethnicity and randomized into eight groups to receive zero, one, two, or three PCV doses at 14 weeks, six and 14 weeks, or six, ten, and 14 weeks. Within each group, half received 23vPPS at 12 months and all received mPPS at 17 months. Sera were taken prior and one month post-mPPS. FINDINGS: By 17 months, geometric mean antibody concentrations (GMC) to all 23 serotypes in 23vPPS were significantly higher in children who had received 23vPPS at 12 months compared to those who had not. Post-mPPS, children who had not received the 12 month 23vPPS had a significantly higher GMC for all PCV serotypes compared with those who had (each p<0.02). For the non-PCV serotypes, children who had not received the 12 month 23vPPS had significantly higher GMC for six of 16 non-PCV serotypes (7F, 9N, 12F, 19A, 22F, 33F) than those who did (each p<0.02). After adjusting for the pre-mPPS level, exposure to 23vPPS was associated with a lower response to mPPS for all serotypes (each p<0.001). INTERPRETATION: Despite higher antibody concentrations at 17 months in children who had received 23vPPS at 12 months, the response to a re-challenge was poor for all 23 serotypes compared to children who had not received the 12 month 23vPPS. Copyright 2010 Elsevier Ltd. All rights reserved.
RCT Entities:
BACKGROUND: To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS). METHODS: Five hundred and fifty-two Fijian infants were stratified by ethnicity and randomized into eight groups to receive zero, one, two, or three PCV doses at 14 weeks, six and 14 weeks, or six, ten, and 14 weeks. Within each group, half received 23vPPS at 12 months and all received mPPS at 17 months. Sera were taken prior and one month post-mPPS. FINDINGS: By 17 months, geometric mean antibody concentrations (GMC) to all 23 serotypes in 23vPPS were significantly higher in children who had received 23vPPS at 12 months compared to those who had not. Post-mPPS, children who had not received the 12 month 23vPPS had a significantly higher GMC for all PCV serotypes compared with those who had (each p<0.02). For the non-PCV serotypes, children who had not received the 12 month 23vPPS had significantly higher GMC for six of 16 non-PCV serotypes (7F, 9N, 12F, 19A, 22F, 33F) than those who did (each p<0.02). After adjusting for the pre-mPPS level, exposure to 23vPPS was associated with a lower response to mPPS for all serotypes (each p<0.001). INTERPRETATION: Despite higher antibody concentrations at 17 months in children who had received 23vPPS at 12 months, the response to a re-challenge was poor for all 23 serotypes compared to children who had not received the 12 month 23vPPS. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Kenneth M Zangwill; David P Greenberg; Chung-Yin Chiu; Paul Mendelman; Victor K Wong; Swei-Ju Chang; Susan Partridge; Joel I Ward Journal: Vaccine Date: 2003-05-16 Impact factor: 3.641
Authors: Reinier Veenhoven; Debby Bogaert; Cuno Uiterwaal; Carole Brouwer; Herma Kiezebrink; Jacob Bruin; Ed IJzerman; Peter Hermans; Ronald de Groot; Ben Zegers; Wietse Kuis; Ger Rijkers; Anne Schilder; Elisabeth Sanders Journal: Lancet Date: 2003-06-28 Impact factor: 79.321
Authors: Catherine Satzke; Belinda D Ortika; Shahin Oftadeh; Fiona M Russell; Roy M Robins-Browne; E Kim Mulholland; Gwendolyn L Gilbert Journal: J Clin Microbiol Date: 2010-09-01 Impact factor: 5.948
Authors: Catherine Satzke; Anna Seduadua; Reginald Chandra; Jonathan R Carapetis; E Kim Mulholland; Fiona M Russell Journal: J Clin Microbiol Date: 2010-07-28 Impact factor: 5.948
Authors: F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland Journal: Clin Vaccine Immunol Date: 2010-10-13
Authors: Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang Journal: J Allergy Clin Immunol Date: 2012-02-02 Impact factor: 10.793
Authors: F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland Journal: Vaccine Date: 2010-10-31 Impact factor: 3.641
Authors: Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland Journal: Vaccine Date: 2014-03-06 Impact factor: 3.641
Authors: Anne Balloch; Paul V Licciardi; Fiona M Russell; Edward K Mulholland; Mimi L K Tang Journal: J Allergy Clin Immunol Date: 2010-06-26 Impact factor: 10.793
Authors: F M Russell; A Balloch; P V Licciardi; J R Carapetis; L Tikoduadua; L Waqatakirewa; Y B Cheung; E K Mulholland; M L K Tang Journal: Vaccine Date: 2011-05-01 Impact factor: 3.641
Authors: Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke Journal: Vaccine Date: 2015-07-29 Impact factor: 3.641